Exogenous Testosterone, Cardiovascular Events, and Cardiovascular Risk Factors in Elderly Men: A Review of Trial Data

Journal of Sexual Medicine

Volumn 9, Issue 1, 2012, Pages 54-67

  Carson Iii, Culley C ^a   Rosano, Giuseppe ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

Author keywords

Cardiovascular Events; Cardiovascular Risk; Elderly Men; Exogenous Testosterone; Hypogonadal; Testosterone Treatment

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANDROGEN DEFICIENCY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMORBIDITY; CONSTRICTIVE PERICARDITIS; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; ELDERLY CARE; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; EXERCISE; EXERCISE TEST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUNG EMBOLISM; META ANALYSIS; METABOLIC SYNDROME X; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84855360204     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02337.x     Document Type: Article

References (59)

1. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: The MINOS study. Am J Clin Nutr 2004;80:496-503.
2. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 2002;57A:M772-7.
3. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76.
4. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009;94:1991-2001.
5. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639-50.
6. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: Molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002;282:E601-7.
7. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
8. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, De BD, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
9. Peltonen M, Harald K, Männistö S, Saarikoski L, Peltomäki P, Lund L, Sundvall J, Juolevi A, Laatikainen T, Aldén-Nieminen H, Luoto R, Jousilahti P, Salomaa V, Taimi M, Vartiainen E. The National FINRISK 2007 Study. Helsinki, Finland: National Public Health Institute; 2008.
10. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: Purported association and clinical implications. Am J Cardiovasc Drugs 2005;5:141-54.
11. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009;6:532-42.
12. Jones TH. Testosterone deficiency: A risk factor for cardiovascular disease? Trends Endocrinol Metab 2010;21:496-503.
13. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318-27.
14. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
15. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation 2006;114:1829-37.
16. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007;19:176-82.
17. Weidemann W, Hanke H. Cardiovascular effects of androgens. Cardiovasc Drug Rev 2002;20:175-98.
18. von Eckardstein A, Wu FC. Testosterone and atherosclerosis. Growth Horm IGF Res 2003;13(A suppl):S72-84.
19. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7.
20. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29-39.
21. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-93.
22. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75.
23. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: A meta-analysis study. Int J Androl 2010 Oct 24 [Epub ahead of print] doi: 10.1111/j.1365-2605.2010.01117.x.
24. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011;8:272-83.
25. Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM. Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial. J Gen Intern Med 2008;23:310-6.
26. Dong X, Mendes de LC, Artz A, Tang Y, Shah R, Evans D. A population-based study of hemoglobin, race, and mortality in elderly persons. J Gerontol A Biol Sci Med Sci 2008;63:873-8.
27. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009;9:1-20.
28. Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: A review. Int J Cardiol 2010;142:8-14.
29. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-4.
30. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
31. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-7.
32. Pugh PJ, Jones RD, Malkin CJ, Hall J, Nettleship JE, Kerry KE, Jones TH, Channer KS. Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res 2005;31:271-83.
33. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
34. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007;9:44-50.
35. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol 2003;92:1241-3.
36. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: Treatment implications. Curr Heart Fail Rep 2010;7:59-65.
37. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008;101:618-24.
38. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-6.
39. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313-8.
40. Smith AM, English KM, Malkin CJ, Jones RD, Jones TH, Channer KS. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 2005;152:285-91.
41. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161:443-9.
42. Cornoldi A, Caminiti G, Marazzi G, Vitale C, Patrizi R, Volterrani M, Miceli M, Fini M, Spera G, Rosano G. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 2010;142:50-5.
43. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-11.
44. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-6.
45. Hernandez-Mijares A, Garcia-Malpartida K, Sola-Izquierdo E, Banuls C, Rocha M, Gomez-Martinez MJ, Marmol R, Victor VM. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010;7:1954-64.
46. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006;295:1288-99.
47. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
48. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156:595-602.
49. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-33.
50. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blind placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-12.
51. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-503.
52. Hanley AJ, Festa A, D'Agostino RB Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: Factor analysis using directly measured insulin sensitivity. Diabetes 2004;53:1773-81.
53. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008;93:139-46.
54. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: A randomized controlled trial. JAMA 2008;299:39-52.
55. Agledahl I, Brodin E, Svartberg J, Hansen JB. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost 2009;102:945-50.
56. Katznelson L, Robinson MW, Coyle CL, Lee H, Farrell CE. Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. Eur J Endocrinol 2006;155:867-75.
57. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, Whyte M, McMillan CV, Bradley C, Martin FC. The effects of growth hormone and/or testosterone in healthy elderly men: A randomized controlled trial. J Clin Endocrinol Metab 2006;91:477-84.
58. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin BA, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.
59. ® 1% (testosterone gel) (prescribing information). Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2009.